While this happened, Stifel initiated its Structure Therapeutics Inc ADR [GPCR] rating to a Buy in a research note published on January 08, 2025; the price target was $50. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Morgan Stanley began covering GPCR with “an Overweight” recommendation on September 23, 2024. JP Morgan started covering the stock on May 21, 2024. It rated GPCR as “an Overweight”.
Price Performance Review of GPCR
On Friday, Structure Therapeutics Inc ADR [NASDAQ:GPCR] saw its stock fall -8.73% to $27.40. Over the last five days, the stock has lost -8.58%. Structure Therapeutics Inc ADR shares have risen nearly 1.03% since the year began. Nevertheless, the stocks have fallen -40.64% over the past one year. While a 52-week high of $62.74 was reached on 01/31/25, a 52-week low of $23.50 was recorded on 01/13/25. SMA at 50 days reached $29.71, while 200 days put it at $37.03.
Levels Of Support And Resistance For GPCR Stock
The 24-hour chart illustrates a support level at 26.25, which if violated will result in even more drops to 25.11. On the upside, there is a resistance level at 29.57. A further resistance level may holdings at 31.74. The Relative Strength Index (RSI) on the 14-day chart is 43.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.98%. Stochastics %K at 53.48% indicates the stock is a holding.
How much short interest is there in Structure Therapeutics Inc ADR?
A steep rise in short interest was recorded in Structure Therapeutics Inc ADR stocks on 2024-10-31, dropping by -0.11 million shares to a total of 10.44 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 10.55 million shares. There was a decline of -1.01%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 09, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
